The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
14 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $6,596,373 in first-year total cost, median $426,496.
Most frequent study sections
- Special Emphasis Panel[ZRG1 BST-F (55)]11
- Xenobiotic and Nutrient Disposition and Action Study Section[XNDA]2
- Clinical and Integrative Diabetes and Obesity Study Section[CIDO]1
Most frequent institutions
- WEILL MEDICAL COLL OF CORNELL UNIV2
- CARNEGIE INSTITUTION OF WASHINGTON, D.C.1
- CLEVELAND CLINIC LERNER COM-CWRU1
- ICAGEN-T, INC.1
- MAYO CLINIC ARIZONA1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | A High Content Chemical Screen to Identify the Drug Candidates Promoting Human Beta Cell Proliferation1R01DK124463-01 | CHEN, SHUIBING | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $423,750 | ZRG1 |
| 2020 | Assay Development for Discovery of a Small Molecule Inhibitor of a Novel Metabolic Pathway that Drives Obesity1R01DK124203-01 | FOX, PAUL L | CLEVELAND CLINIC LERNER COM-CWRU, OH | $401,875 | ZRG1 |
| 2020 | Assay Development and Optimization for High Throughput Screen to Detect Compounds Increasing Secretion of C150S Mutant Uromodulin1R01DK119631-01A1 | WOLF, MATTHIAS TILMANN FLORIAN | UT SOUTHWESTERN MEDICAL CENTER, TX | $359,150 | ZRG1 |
| 2019 | Small molecules for expansion of islet beta-cell mass in diabetes1R01DK120623-01 | NEWGARD, CHRISTOPHER BSEXTON, JONATHAN ZACHARY | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $684,336 | CIDO |
| 2019 | High-throughput screening for modulators of vascular fat transport to treat and prevent diabetes1R01DK119656-01 | ARANY, ZOLTAN PAUGUST, PAUL | ICAGEN-T, INC., AZ | $632,099 | ZRG1 |
| 2019 | Screening and Development of Small Molecule HDAC11 Inhibitors to Treat Obesity and Diabetes.1R01DK119594-01 | LIN, HENINGMCKINSEY, TIMOTHY | UNIVERSITY OF COLORADO DENVER, CO | $559,407 | ZRG1 |
| 2019 | Development of Distal Nephron Diuretics Targeting Kir4.1/5.1 Heteromeric Potassium Channels1R01DK120821-01A1 | DENTON, JEROD S. | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $429,242 | ZRG1 |
| 2018 | In vivo HTS assay for novel modulators of Apolipoprotein B1R01DK116079-01A1 | FARBER, STEVEN A | CARNEGIE INSTITUTION OF WASHINGTON, D.C., DC | $682,895 | ZRG1 |
| 2018 | An in vivo screening system for chemical modulators of eating behavior1R01DK117872-01 | OSBORN, OLIVIA DPETRASCHECK, MICHAEL | SCRIPPS RESEARCH INSTITUTE, THE, CA | $625,501 | XNDA |
| 2018 | Inhibitors of Intestinal Epithelial Cell Lysosomal-Mediated Necrosis1R01DK114047-01A1 | LUKE, CLIFFORD JAMESSILVERMAN, GARY ARTHUR | WASHINGTON UNIVERSITY, MO | $454,366 | XNDA |
| 2018 | A High Throughput Screening to Identify Compounds Rescuing Human Pancreatic Beta Cell Function in Diabetic Conditions1R01DK116075-01A1 | CHEN, SHUIBING | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $423,750 | ZRG1 |
| 2018 | Universal positive allosteric modulators of CCK1R without intrinsic agonist activity for the treatment of obesity1R01DK115402-01A1 | MILLER, LAURENCE J | MAYO CLINIC ARIZONA, AZ | $415,000 | ZRG1 |
| 2018 | Designing selective TALK-1 inhibitors to reduce beta-cell dysfunction in diabetes1R01DK115620-01 | JACOBSON, DAVID AARON | VANDERBILT UNIVERSITY, TN | $392,397 | ZRG1 |
| 2018 | Identification of Hypoxia-Inducible Factor-2alpha Activators for Chronic Kidney Disease Anemia1R01DK118297-01 | RASTINEJAD, FRAYDOON | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $112,605 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.